Fas Engagement Induces the Maturation of Dendritic Cells (DCs), the Release of Interleukin (IL)-1β, and the Production of Interferon γ in the Absence of IL-12 during DC–T Cell Cognate Interaction: A New Role for Fas Ligand in Inflammatory Responses

By Maria Rescigno,* Vincent Piguet,‡ Barbara Valzasina,* Suzanne Lens,§ Rudolf Zubler,‖ Lars French,‡ Vincent Kindler,‖ Jurg Tschopp,§ and Paola Ricciardi-Castagnoli*

From the *Department of Biotechnology and Bioscience, University of Milano-Bicocca, 20126 Milan, Italy; the ‡Department of Dermatology, Hôpitaux Universitaires de Genève, Département Hospitalo-Universitaire Romand de Dermatologie et Vénéréologie, CH-1211 Geneva, Switzerland; the §Institut de Biochimie, University of Lausanne, CH-1066 Épalinges, Switzerland; and the ‖Division of Hematology, Hôpitaux Universitaires Vaudois et Genevois, CH-1211 Geneva, Switzerland

Abstract

Ligation of the Fas (CD95) receptor leads to an apoptotic death signal in T cells, B cells, and macrophages. However, human CD34+–derived dendritic cells (DCs) and mouse DCs, regardless of their maturation state, are not susceptible to Fas-induced cell death. This resistance correlates with the constitutive expression of the Fas-associated death domain–like IL-1β–converting enzyme (FLICE)-inhibitory protein (FLIP) ligand. We demonstrate a new role of Fas in DC physiology. Engagement of Fas on immature DCs by Fas ligand (FasL) or by anti-Fas antibodies induces the phenotypical and functional maturation of primary DCs. Fas-activated DCs upregulate the expression of the major histocompatibility complex class II, B7, and DC–lysosome-associated membrane protein (DC-LAMP) molecules and secrete proinflammatory cytokines, in particular interleukin (IL)-1β and tumor necrosis factor α. Mature DCs, if exposed to FasL, produce even higher amounts of IL-1β. Importantly, it is possible to reduce the production of IL-1β and interferon (IFN)–γ during DC–T cell interaction by blocking the coupling of Fas–FasL with a Fas competitor. Finally, during cognate DC–T cell recognition, IL-12 (p70) could not be detected at early or late time points, indicating that Fas-induced, IFN-γ secretion is independent of IL-12.

Key words: dendritic cells • Fas • interleukin 1β • FLIP • interferon γ

Introduction

The first step in any adaptive immune response is the activation of naive T cells in the LN. Once stimulated by infection, dendritic cells (DCs) migrate to the draining LN where naive T cells circulate and can encounter their specific antigen on the DC surface (1). Because this is a rare event, the prolongation of cell survival and the correct activation state of DCs are of primary importance in order to control and sustain the immune response.

We have previously reported that DCs express the Fas receptor (CD95) (2), but its role on DCs is still a matter of debate (3, 4). Stimulation of the Fas receptor normally induces an apoptotic death signal. However, in T cells the interactions between Fas and Fas ligand (FasL) do not always induce a death signal (5). Indeed, depending on the state of T cell activation, Fas–FasL interaction can also lead to T cell activation and proliferation (6, 7). Thus, signaling through Fas in the early stages of an immune response might amplify the T cell response, whereas the signaling through Fas could downsize the response via apoptosis of T cells in later stages. Upon Fas activation and trimerization, a set of effector proteins is recruited to this receptor, forming...
the death inducing signaling complex. Fas-associated death domain (FADD), the first protein that binds to Fas, recruits caspase-8, initiating a cascade of events resulting in efficient cell death (8). Fas-induced apoptosis can be blocked by FADD-like IL-1β-converting enzyme (FLICE)-inhibitory proteins (FLIPs) (9). Furthermore, FLIP mediates the activation of nuclear factor κB and extracellular signal-regulated kinase (Erk), diverting Fas-mediated death signals into signals that lead to proliferation and/or differentiation (10). Both of these signaling pathways are activated by LPS and play important roles in DC maturation and survival (11).

Recently, the disregulation of Fas–FasL interactions has been considered as one of the major causes of exaggerated immune responses, such as organ-specific autoimmune diseases (12). In insulin-dependent diabetes mellitus, β islet cells express Fas on their surface in response to IL-1β and become susceptible to Fas-induced cell death by activated T cells (12).

In this study, we confirm that Fas is unable to induce DC death due to a constitutive FLIP expression and further demonstrate that FasL triggers both a phenotypical and functional maturation of DCs, as well as the secretion of proinflammatory cytokines, in particular IL-1β and TNF-α.

Materials and Methods

Cells and Reagents. Purification of human CD34+ cells, primary culture with FLT3-L, thrombopoietin, and stem cell factor, and induction of DCs were performed as described previously (13). Two growth factor–dependent DC mice lines, D1 and D8, were used as well as bone marrow–derived fresh DCs (2, 14) and were grown as described previously (2, 14). Bone marrow cells were grown for 15–20 d and the homogeneity of the DC culture was evaluated by cytofluorimetry. CD4+ T cells were purified from TCR-OVA DO11.10 transgenic mice, bred in BALB/c background, by positive selection with an anti-CD4 antibody coupled to magnetic microbeads, using MiniMacS Separating columns (all from Miltenyi Biotec). LPS (Escherichia coli, serotype 026:B6) was purchased from Sigma-Aldrich. FasL and anti-Flag Enhancer were from Alexis, and Fas competitor (Fas–comp) was derived as described (15). Human GM-CSF (Leucomax) was purchased from Essex Chimie & Sandoz and used at 20 ng/ml. Other human cytokines were purchased from Peprotech and used at the following concentrations: FLT3-L at 25 ng/ml, thrombopoietin at 10 U/ml, stem cell factor at 20 ng/ml, IL-4 at 20 ng/ml (100 U/ml), and TNF at 40 ng/ml (200 U/ml).

Cell Stimulation, Antibodies, and Flow Cytometry Analysis. Human DCs were incubated with TNF-α (or anti-Flag Enhancer) and FasL (Alexis) for 18–24 h at the indicated concentrations. Cultured cells were stained with specific labeled mAbs or appropriate isotypic controls and incubated in 300 μl of saline, 3% FCS containing 10 μg/ml of 7-aminotetrazolium (7AAD; Sigma-Aldrich) (16). Data were analyzed using WINMDI software by J. Trotter (Scripps Institute, La Jolla, CA). For intracellular staining, cells were incubated with mouse IgM anti-DC-LAMP, anti-CD86, and anti–HLA-DR (clone L243) from Becton Dickinson, anti-CD80 (clone BB1) and anti-CD86 (clone IT2.2) from BD PharMingen. Anti–DC-LAMP antibody (clone 510 F1.65.13) was a gift of Dr. S. Lebeque (Schering-Plough, Dardilly, France). Other reagents used were as follows: polyclonal mouse IgG reagent grade from Sigma-Aldrich and anti-CD34 mIgG-coated M450 Dynabeads from Dynal. LPS-matured or nontreated murine DCs were cultured either with anti-Flag Enhancer and FasL, anti-CD95 (Jo-2), or an isotype-matched control, at the indicated concentrations.

After activation, cells were incubated with one of the following mAbs from BD PharMingen: anti–[I-A/1−I-E]/ (2G9), anti-CD86 (B7.2), anti-CD95 (Jo-2), or hamster IgG (G235–2356). Staining was carried out in the presence of 2–4G2 to block Fc receptor binding. For each sample, culture supernatants were collected for the cytokine production assay.

Quantification of FLIP. Human DC34+-derived DCs (5 × 10^6) were lysed in 50 μl of lysis buffer (1% NP-40, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and Complete™ protease inhibitor cocktails tablets [Boehringer]). 30 μg of protein per lane was subjected to electrophoresis under reducing conditions and transferred to nitrocellulose (Hybond ECL; Amersham Pharmacia Biotech). Blots were probed with anti-FLIP mAbs (Dave 2; Alexis), visualized using horseradish peroxidase–labeled, anti-rat Abs (Southern Biotechnology Associates, Inc.), and ECL blotting substrate (Amersham Pharmacia Biotech). Quantification on films was performed using the ONE D-Scan program (Scanalytics) as described previously (17).

Results

Fas Is Constitutively Expressed by DCs and Is Upregulated by LPS or TNF-α. Similar to mouse DCs (2), nonstimulated immature, human CD34+-derived DCs were found to express Fas (Fig. 1A). Therefore, we studied the regulation of
Fas during maturation of human and mouse DCs induced by TNF-α or LPS. Incubation of human DCs with 40 ng/ml of TNF-α (Fig. 1 A) or LPS (data not shown) for 24 h induced a slight upregulation of Fas. We next incubated a well-defined, mouse spleen long-term growth factor–dependent DC line (D1 cells) or primary murine bone marrow–derived DCs (mBM-DCs) with LPS (10 μg/ml), which induced a significant upregulation of Fas that was more pronounced in primary mBM-DCs (compare Fig. 1, B and C). Interestingly, incubation of agonistic anti-Fas antibodies (Jo-2) resulted in a dose-dependent downregulation of Fas (not shown) at early time points and in the upregulation of Fas at late time points (not shown).

DCs Are Resistant to Fas-induced Apoptotic Cell Death. Since the induction of cell death by FasL remains controversial (3, 4, 18), we have studied the effects of FasL or the Jo-2 antibody on DCs. As shown in Fig. 2, A and B, both human and mouse DCs were resistant to Fas-induced cell death. Human CD34+–derived immature DCs or 72-h, TNF-matured DCs (data not shown) were treated with FasL and enhancer for 24 h and analyzed using 7AAD staining (see Materials and Methods). No significant increase of dead and apoptotic cells was noticed after FasL treatment for 24 h in immature DCs (Fig. 2 A) or TNF-matured DCs (data not shown). D1 cells and mBM-DCs, pretreated or not with LPS for 20 h, were incubated with different concentrations of anti-Fas antibody for 6 h. Cells were double-stained with FITC-conjugated annexin V and with propidium iodide. Cells single positive for annexin V were considered as undergoing early apoptosis. As shown in Fig. 2 B, regardless of the concentration of anti-Fas used, a maximum 10% of the D1 cells underwent apoptosis (when subtracting the amount of apoptotic cells after LPS treatment), and no apoptosis was observed when anti-Fas was tested on immature cells. Similar results were obtained with fresh mBM-DCs (not shown). Finally, no significant cell death occurred in mature or immature DCs during cognate DC–T cell interaction (not shown).

DCs Constitutively Express FLIP. Fas-induced apoptosis can be blocked during signal transduction by FLIPs (9). We observed by Western blot analysis that FLIP was constitutively expressed by human and mouse DCs. Further-
more, FLIP was upregulated approximately twofold at 24 h of DC incubation with FasL in human DCs (Fig. 2, C and D). A similar upregulation of FLIP was observed after FasL, TNF-α, or LPS treatment in either human or mouse DCs (data not shown).

**Fas Induces Phenotypical Maturation of DCs.** Subsequently, we examined the potential role of FasL in DC maturation (Fig. 3). Human (Fig. 3 A) and mouse (Fig. 3 B) DCs were incubated for 18–24 h with 0.1 μg/ml FasL and with 0.5 μg/ml of enhancer. This stimulus induced a strong upregulation of maturation markers such as MHC class II, CD40, CD80, CD83, and CD86 on the cell surface of human CD34⁺–derived DCs as well as of intracellular DC-LAMP (Fig. 3 A). The extent of maturation induced by FasL treatment was comparable to that induced by TNF-α or LPS (data not shown). Moreover, human and mouse DCs could be activated by FasL, but not by boiled FasL, excluding a possible endotoxin contamination. The effect of FasL was reproduced by the Jo-2 antibody. As shown in Fig. 3 C, as low as 0.01 μg/ml of Jo-2 antibody was sufficient to induce the maturation of both primary mBM-DCs and the D1 cell line, whereas an isotype control for the Jo-2 antibody had no effect (Fig. 3 C).

**Fas Induces Functional Activation of Immature and Mature DCs.** Cytokine secretion by DCs was tested in culture supernatants after Fas engagement and was compared with that induced by LPS (Fig. 4). Although the amount of TNF-α produced was comparable among LPS- and Fasmatured DCs (Fig. 4 A), Fas-matured DCs secreted more IL-1β (Fig. 4 B). If LPS-matured DCs were subsequently exposed to anti-Fas antibody, the production of IL-1β greatly increased (600 vs. 20 pg/ml with LPS alone, Fig. 4 B) as well as the amount of secreted IL-10 (Fig. 4 C). In contrast, the amount of bioactive IL-12 (p70) secreted was very low in Fas-matured DCs (Fig. 4 D). When we analyzed fresh mBM-DCs, similar results were obtained (Fig. 5, A and B).

**Blocking Fas–FasL Interaction during Cognate DC–T Cell Interaction Partly Inhibits the Production of IL-1β and IFN-γ.** To gain insight on the functional activation of DCs by FasL, we measured cytokine production by DCs during antigen-specific T cell proliferation in the presence or ab-

---

**Figure 3.** Fas engagement triggers the phenotypical maturation of human and mouse DCs. (A) Surface expression of cellular receptors and intracellular expression of DC-LAMP in human CD34⁺–derived DCs treated with 0.1 μg/ml FasL plus 0.5 μg/ml Enhancer for 24 h (black line) versus 0.1 μg/ml boiled FasL plus 0.5 μg/ml Enhancer (gray line), or isotype control mAbs (dotted gray line). Results are representative of four independent experiments. (B) Comparison of B7.2 (CD86) upregulation by LPS (left) or FasL plus Enhancer (right) in mouse D1 cells. (C) Treatment of DCs (D1 cells, left; mBM-DCs, right) by anti-CD95 antibody (Jo-2) with concentrations ranging between 0.01 and 10 μg/ml or an isotype control (thin line). Results are representative of three independent experiments.
sence of a Fas-comp (15). CD4+ T cells were purified from TCR-OVA DO11.10 mice and incubated with a homogenous mouse bone marrow–derived, long-term DC line (D8; T/DC, 5:1) in the presence of varying concentrations of OVA 327–339 peptide, with or without 0.5 μg/ml Fas-comp. This concentration of competitor completely inhibited Fas-induced activation of DCs (not shown). As shown in Fig. 6 A, T cell proliferation was not reduced in the presence of Fas-comp; rather, an increase in thymidine uptake was observed in the presence of Fas-comp, probably because of a direct interaction with FasL on T cells. Consistently, the amount of IL-2 produced increased in the presence of Fas-comp. In contrast, DCs were impaired in their capacity to secrete IL-1β, as shown by the inhibition of cytokine released 48 h after DC–T cell interaction in the presence of Fas-comp (Fig. 6 C). Although the production of IL-2 by T cells was increased in the presence of Fas-comp, the amount of IFN-γ produced was reduced (Fig. 6 D), suggesting an important role of Fas–FasL interaction for the polarization of T cells. The reduced inhibition of IFN-γ observed at 48 h of antigen presentation could result from a suboptimal amount of Fas-comp when T cells are actively proliferating. Interestingly, the production of IFN-γ was not dependent on IL-12 secretion because bioactive IL-12 (p70) could not be detected in culture supernatants throughout the entire proliferative response (Fig. 6 E).

**Discussion**

Unlike B cells and macrophages, which are susceptible to Fas-induced cell death (19–21), DCs are largely resistant to Fasl. Although it has been reported that murine DCs undergo apoptosis after cognate T cell interaction, partly mediated by Fas–FasL interaction (4), several studies have shown that, in vivo, T cells induce survival of DCs (22), and that in vitro, neither T cells nor FasL induce DC death (3, 18). In this report, we confirm that DCs are resistant to
Fas-mediated cell death, irrespective of their maturation stage. This resistance correlates with the constitutive expression of DCs of FLIP, an intracellular inhibitor of apoptosis.

DCs have the unique capacity to prime T cells, and the costimulatory surface molecules B7 and CD40 contribute to this function (1). The counterpart of B7 on T cells, CD28 for instance, increases the duration of TCR signaling which correlates with T cell activation (23). A noncanonical costimulatory molecule expressed on T cells is Fas. The engagement of Fas on naive T cells, in suboptimal stimulation via the TCR, induces the proliferation of T cells (7, 24). Conversely, activated CTLs or Th1 cells express high levels of FasL (25); Fas–FasL interaction on T cells (7, 24). Conversely, activated CTLs or Th1 cells express high levels of FasL (25); Fas–FasL interaction on T cells (7, 24). A recent report, in agreement with this hypothesis, shows that transgenic nonobese diabetic mice expressing FasL in β cells are more sensitive to diabetogenic T cells (28) in a FasL-dependent manner. Since transgenic β cells were also expressing higher amounts of Fas, it is possible that these cells, by expressing FasL, were directly activating DCs for IL-1β production, which in turn would be responsible for Fas induction. Accordingly, transplantation of the fetal pancreas from transgenic mice expressing murine CD95L on their β islet cells under the kidney capsules of allogeneic animals resulted in rapid graft rejection (29).

Though murine myeloid DCs did not secrete IL-12 after Fas ligation, T cells did produce IFN-γ in a Fas–FasL-dependent manner. A Fas-comp did not affect T cell proliferation and IL-2 production. Rather, an increased proliferation was observed, suggesting that Fas expressed on DCs may have a dual role as both the activator of T cell proliferation and the director of T cell polarization into a Th1 phenotype, even in the absence of IL-12. Further experiments on the effects of Fas–FasL interaction on T cells will be needed to address this question.
Finally, our results demonstrate that Fas–FasL interaction induces the maturation of DCs, the secretion of large amounts of IL-1β by DCs, and drives the polarization of T cells into a Th1 phenotype. These findings explain, at least in part, the adverse effects obtained by the transgenic expression of FasL in transplanted organs (28, 29) and puts clear constraints on the therapeutic use of FasL in autoimmune diseases.

We thank Dr. S. Lebecque for providing us with the anti–DC-LAMP antibody, and F. Leuba (Department of Dermatology, University Hospital of Geneva) for his technical assistance.

This work was supported by grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC), the European Community Mucosal Immunization and Vaccine Development (MUCIMM) contract, and a grant from the Leenaards Foundation (to V. Piguet and L. French).

Submitted: 14 July 2000
Revised: 2 October 2000
Accepted: 7 October 2000

References

1. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245–252.
2. Winzler, C., P. Rovere, M. Rescigno, F. Granucci, G. Penna, L. Adorini, V.S. Zimmermann, J. Davoust, and P. Ricciardi-Castagnoli. 1997. Maturation stages of mouse dendritic cells in growth factor–dependent long-term cultures. J. Exp. Med. 185:317–328.
3. Ashany, D., A. Savir, N. Bhardwaj, and K.B. Elkon. 1999. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J. Immunol. 163:5303–5311.
4. Matsue, H., D. Edelbaum, A.C. Hartmann, A. Morita, P.R. Bergstresser, Y. Yagita, K. Okumura, and A. Takashima. 1999. Dendritic cells undergo rapid apoptosis in vitro during antigen-specific interaction with CD4+ T cells. J. Immunol. 162:5287–5298.
5. Lynch, D.H., F. Ramsdell, and M.R. Alderson. 1995. Fas and FasL in the homeostatic regulation of immune responses. ImmunoL Today. 16:569–574.
6. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969–976.
7. Kennedy, N.J., T. Kataoka, J. Tschopp, and R.C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190:1891–1896.
8. Tschopp, J., M. Irmler, and M. Thome. 1998. Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 10:552–558.
9. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.L. Bodmer, M. Schroter, K. Burns, C. Kindler, and et al. 1997. Inhibition of death receptor signals by cellular FLIP. Nature. 388:190–195.
10. Kataoka, T., R.C. Budd, N. Holler, M. Thome, F. Martignon, M. Irmler, K. Burns, M. Hahne, N. Kennedy, M. Kovacsovics, and J. Tschopp. 2000. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 10:640–648.
11. Rescigno, M., M. Martino, C.L. Sutherland, M.R. Gold, and F. Ricciardi-Castagnoli. 1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188:2175–2180.
12. De Maria, R., and R. Testi. 1998. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol. Today. 19:121–125.
13. Arrighi, J.F., C. Hauser, B. Chapuis, R.H. Zuber, and V. Kindler. 1999. Long-term culture of human CD34+ progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34+CD14+ and a CD34+CD14+ dendritic cell precursor. Blood. 93:2244–2252.
14. Citerio, S., M. Rescigno, M. Foti, F. Granucci, D. Agguraro, C. Gasperi, M. Matyszak, G. Girolomoni, and P. Ricciardi-Castagnoli. 1999. Dendritic cells as natural adjuvants. Methods. 19:142–147.
15. Holler, N., T. Kataoka, J.L. Bodmer, P. Romero, J. Romero, D. Deperthes, J. Engel, J. Tschopp, and P. Schneider. 2000. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J. Immunol. Methods. 237:159–173.
16. Schmid, I., C.H. Uittenbogaart, and J.V. Giorgi. 1994. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry. 15:12–20.
17. Piguet, V., F. Gu, M. Foti, N. Demaurex, J. Gruenewald, J.L. Carpenter, and D. Trono. 1999. Nef-induced CD4 degradation: a diacidic–based motif in Nef functions as a lysosomal targeting signal through the binding of β-COP in endosomes. Cell. 97:63–73.
18. Willem, F., Z. Amraoui, N. Vanderheyde, V. Verhasselt, E. Aksoy, C. Scaffidi, M.E. Peter, P.H. Krammer, and M. Goldman. 2000. Expression of c-FLIP(L) and resistance to CD95-mediated apoptosis of monococyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood. 95:3478–3482.
19. Rothstein, T.L., J.K. Wang, D.J. Panka, L.C. Foote, Z. Wang, B. Stanger, H. Cui, S.T. Ju, and A. Marshall-Rothstein. 1995. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature. 374:163–165.
20. Ashany, D., X. Song, E. Lacy, J. Nikolic-Zugic, S.M. Friedman, and K.B. Elkon. 1995. Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc. Natl. Acad. Sci. USA. 92:11225–11229.
21. Richardson, B.C., N.D. Lalwani, K.J. Johnson, and R.M. Marks. 1994. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur. J. Immunol. 24:2640–2645.
22. De Smedt, T., B. Pajak, G.G. Klaus, R.J. Noelle, J. Urbain, O. Leo, and M. Moser. 1998. Antigen–specific T lymphocytes regulate lipopolysaccharide–induced apoptosis of dendritic cells in vivo. J. Immunol. 161:4476–4479.
23. Iezzi, G., K. Karjalainen, and A. Lanzavecchia. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 8:89–95.
24. Alderson, M.R., R.J. Armitage, E. Maraskovsky, T.W. Tough, E. Roux, K. Schooley, F. Ramsdell, and D.H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178:2231–2235.
25. Suda, T., T. Okazaki, Y. Naito, T. Yokota, N. Arai, S. Ozaki, K. Nakao, and S. Nagata. 1995. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:3806–3813.
26. Miwa, K., M. Asano, R. Horai, Y. Iwakura, S. Nagata, and T. Suda. 1998. Caspase 1-independent IL-1β release and in-
flammation induced by the apoptosis inducer Fas ligand. *Nat. Med.* 4:1287–1292.

27. Stassi, G., R. De Maria, G. Trucco, W. Rudert, R. Testi, A. Galluzzo, C. Giordano, and M. Trucco. 1997. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. *J. Exp. Med.* 186:1193–1200.

28. Chervonsky, A.V., Y. Wang, F.S. Wong, I. Visintin, R.A. Flavell, C.A. Janeway, Jr., and L.A. Matis. 1997. The role of Fas in autoimmune diabetes. *Cell.* 89:17–24.

29. Allison, J., H.M. Georgiou, A. Strasser, and D.L. Vaux. 1997. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. *Proc. Natl. Acad. Sci. USA.* 94:3943–3947.